Chapter/Section Purchase

1 Study Coverage
1.1 Metachromatic Leukodystrophy (MLD) Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 AGT-183
1.2.3 DUOC-01
1.2.4 GSK-2696274
1.2.5 Others
1.3 Market by Application
1.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region
2.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Metachromatic Leukodystrophy (MLD) Treatment by Region (2023-2028)
2.5 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region
2.5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2017-2022)
2.5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers
3.1.1 Global Top Metachromatic Leukodystrophy (MLD) Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment in 2021
3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers
3.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Metachromatic Leukodystrophy (MLD) Treatment Revenue in 2021
3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type
4.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2017-2028)
4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type
4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type
4.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2017-2022)
4.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application
5.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2017-2028)
5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application
5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application
5.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2017-2022)
5.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
6.1.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
6.1.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
6.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
6.2.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
6.2.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
6.3 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
6.3.1 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
6.3.2 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
7.1.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
7.1.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
7.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
7.2.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
7.2.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
7.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
7.3.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
7.3.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
8.1.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
8.2.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region
8.3.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
9.1.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
9.1.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
9.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
9.2.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
9.2.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
9.3 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
9.3.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
9.3.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
10.1.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
10.2.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
10.3.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 ArmaGen Inc
11.1.1 ArmaGen Inc Corporation Information
11.1.2 ArmaGen Inc Overview
11.1.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ArmaGen Inc Recent Developments
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Corporation Information
11.2.2 GlaxoSmithKline Plc Overview
11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Plc Recent Developments
11.3 Recursion Pharmaceuticals Inc
11.3.1 Recursion Pharmaceuticals Inc Corporation Information
11.3.2 Recursion Pharmaceuticals Inc Overview
11.3.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Recursion Pharmaceuticals Inc Recent Developments
11.4 RegenxBio Inc
11.4.1 RegenxBio Inc Corporation Information
11.4.2 RegenxBio Inc Overview
11.4.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 RegenxBio Inc Recent Developments
11.5 Takeda
11.5.1 Takeda Corporation Information
11.5.2 Takeda Overview
11.5.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Takeda Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Chain Analysis
12.2 Metachromatic Leukodystrophy (MLD) Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process
12.4 Metachromatic Leukodystrophy (MLD) Treatment Sales and Marketing
12.4.1 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels
12.4.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
12.5 Metachromatic Leukodystrophy (MLD) Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
13.2 Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
13.3 Metachromatic Leukodystrophy (MLD) Treatment Market Challenges
13.4 Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
14 Key Findings in The Global Metachromatic Leukodystrophy (MLD) Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer